MeSH term
Frequency | Condition_Probility | Animals | 105 | 0.0 |
Humans | 322 | 0.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
Adolescent | 7 | 0.0 |
Adult | 16 | 0.0 |
Aged | 19 | 0.0 |
Child | 8 | 0.0 |
Child, Preschool | 4 | 0.0 |
Female | 46 | 0.0 |
Infant | 5 | 0.0 |
Male | 37 | 0.0 |
Middle Aged | 18 | 0.0 |
Genes, Tumor Suppressor | 11 | 1.0 |
Cell Aging | 6 | 6.0 |
Cell Cycle | 31 | 2.0 |
Genes, p16 | 5 | 5.0 |
Models, Biological | 8 | 0.0 |
Protein p16/*metabolism | 3 | 9.0 |
Retinoblastoma Protein/*metabolism | 14 | 7.0 |
Apoptosis | 10 | 0.0 |
CDC2-CDC28 Kinases/metabolism | 9 | 20.0 |
Cell Differentiation | 4 | 0.0 |
Cell Line, Tumor | 9 | 0.0 |
Cells, Cultured | 34 | 0.0 |
Cyclin-Dependent Kinases/*physiology | 4 | 8.0 |
G1 Phase | 29 | 9.0 |
Immunoblotting | 8 | 0.0 |
Immunohistochemistry | 12 | 0.0 |
Mice | 59 | 0.0 |
Mice, Knockout | 6 | 0.0 |
Mice, Transgenic | 7 | 0.0 |
RNA, Messenger/metabolism | 10 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 121 | 0.0 |
S Phase | 10 | 3.0 |
Time Factors | 12 | 0.0 |
Transgenes | 2 | 0.0 |
Cell Cycle/genetics | 3 | 2.0 |
Cell Division/genetics | 5 | 1.0 |
Comparative Study | 24 | 0.0 |
Cyclin-Dependent Kinases/genetics/*physiology | 4 | 44.0 |
Cyclins/biosynthesis/genetics | 2 | 4.0 |
Genes, Retinoblastoma | 3 | 3.0 |
Genes, p53 | 2 | 0.0 |
Protein Binding | 23 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/*physiology | 2 | 5.0 |
*Proto-Oncogene Proteins | 103 | 6.0 |
Recombinant Fusion Proteins/physiology | 6 | 2.0 |
*Repressor Proteins | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 231 | 0.0 |
Retinoblastoma Protein/*physiology | 5 | 15.0 |
Amino Acid Sequence | 42 | 0.0 |
Base Sequence | 46 | 0.0 |
Carrier Proteins/genetics/metabolism | 3 | 1.0 |
*Cell Cycle Proteins | 80 | 6.0 |
Cloning, Molecular | 18 | 0.0 |
Molecular Sequence Data | 66 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Sequence Alignment | 5 | 0.0 |
Chromosome Mapping | 11 | 0.0 |
*Cyclin-Dependent Kinases | 38 | 20.0 |
Gene Expression Regulation | 8 | 0.0 |
Protein-Serine-Threonine Kinases/*genetics/metabolism | 4 | 6.0 |
*Translocation, Genetic | 4 | 0.0 |
*Chromosomes, Human, Pair 11 | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*genetics | 5 | 1.0 |
*Proto-Oncogenes | 2 | 0.0 |
*Transcription Factors | 3 | 0.0 |
Cell Cycle/*physiology | 12 | 4.0 |
Cell Cycle Proteins/*metabolism | 6 | 1.0 |
Cyclin D1/metabolism | 9 | 6.0 |
Cyclin-Dependent Kinases/*metabolism | 27 | 10.0 |
Cyclins/*metabolism | 22 | 8.0 |
DNA Primers/chemistry | 4 | 0.0 |
Flow Cytometry | 17 | 0.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
Phosphorylation | 55 | 0.0 |
Precipitin Tests | 12 | 0.0 |
Retinoblastoma Protein/metabolism | 47 | 13.0 |
Thymidine/metabolism | 2 | 0.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Cell Nucleus/metabolism | 5 | 0.0 |
*Genes, p16 | 9 | 9.0 |
Mutation | 19 | 0.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Protein p16/*genetics/metabolism | 3 | 15.0 |
Protein-Serine-Threonine Kinases/*metabolism | 21 | 3.0 |
RNA, Messenger/genetics | 4 | 0.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Tumor Cells, Cultured | 118 | 0.0 |
Antineoplastic Agents/*pharmacology | 13 | 1.0 |
*Apoptosis | 6 | 0.0 |
Blotting, Northern | 8 | 0.0 |
Blotting, Western | 30 | 0.0 |
Calcitriol/*analogs & derivatives/*pharmacology | 2 | 16.0 |
Cell Division | 28 | 0.0 |
Cyclins/biosynthesis | 3 | 3.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Membrane Potentials/drug effects | 2 | 1.0 |
*Proto-Oncogene Proteins c-bcl-2 | 2 | 0.0 |
Signal Transduction | 14 | 0.0 |
Transforming Growth Factor beta/*pharmacology | 10 | 2.0 |
Up-Regulation | 11 | 0.0 |
Binding Sites | 12 | 0.0 |
Crystallography, X-Ray | 4 | 0.0 |
Enzyme Activation | 15 | 0.0 |
Enzyme Inhibitors/pharmacology | 9 | 0.0 |
Models, Molecular | 8 | 0.0 |
Protein Conformation | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 21 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Substrate Specificity | 6 | 0.0 |
*Gene Expression Profiling | 4 | 0.0 |
*Gene Expression Regulation, Neoplastic | 10 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 13 | 0.0 |
Cyclins/metabolism | 32 | 7.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Circular Dichroism | 3 | 0.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors | 16 | 11.0 |
Kinetics | 12 | 0.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Thermodynamics | 2 | 0.0 |
*Cell Division | 2 | 1.0 |
Cyclins/genetics/physiology | 2 | 22.0 |
English Abstract | 4 | 0.0 |
Fibroblasts | 2 | 0.0 |
Protein p53/physiology | 4 | 5.0 |
Retinoblastoma Protein/physiology | 4 | 11.0 |
Apoptosis/*drug effects | 10 | 1.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Phosphorylation/drug effects | 11 | 1.0 |
Biological Markers/analysis | 2 | 0.0 |
*CDC2-CDC28 Kinases | 46 | 6.0 |
Caspases/metabolism | 12 | 1.0 |
Cattle | 2 | 0.0 |
Cell Count | 3 | 0.0 |
Cell Division/drug effects/physiology | 4 | 1.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/metabolism | 5 | 9.0 |
G1 Phase/drug effects | 8 | 7.0 |
Mitogen-Activated Protein Kinases/metabolism | 5 | 0.0 |
Organ Specificity | 7 | 0.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/metabolism | 7 | 8.0 |
Species Specificity | 3 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Cell Cycle Proteins/*genetics | 2 | 1.0 |
Cyclin-Dependent Kinases/analysis | 2 | 11.0 |
Prognosis | 6 | 0.0 |
Apoptosis/*physiology | 2 | 0.0 |
Cyclins/physiology | 5 | 12.0 |
Leukemia, B-Cell, Chronic/metabolism/*pathology | 2 | 25.0 |
Tumor Suppressor Proteins/metabolism | 6 | 5.0 |
*Gene Amplification | 2 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Rats | 10 | 0.0 |
DNA Primers | 9 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Genes, Structural | 3 | 0.0 |
Polymerase Chain Reaction | 17 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
*Gene Rearrangement | 2 | 0.0 |
Immunophenotyping | 3 | 0.0 |
Transcription, Genetic | 8 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Mice, Nude | 3 | 0.0 |
Protein p16/*genetics | 5 | 5.0 |
Transfection | 28 | 0.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 5 | 3.0 |
Cell Cycle/drug effects | 12 | 2.0 |
*DNA-Binding Proteins | 8 | 0.0 |
G1 Phase/*drug effects/physiology | 3 | 30.0 |
Stilbenes/*pharmacology | 3 | 5.0 |
Cell Cycle Proteins/metabolism | 11 | 3.0 |
Cell Division/drug effects | 26 | 0.0 |
Cyclin-Dependent Kinases/metabolism | 45 | 13.0 |
G1 Phase/*drug effects | 17 | 22.0 |
Proto-Oncogene Proteins/metabolism | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 5 | 1.0 |
Signal Transduction/physiology | 3 | 0.0 |
Cell Adhesion | 2 | 0.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Cyclin D1/genetics/metabolism | 2 | 8.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
G1 Phase/*physiology | 5 | 10.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 34 | 4.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Proteins/metabolism | 3 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 5 | 0.0 |
Anticarcinogenic Agents/*pharmacology | 3 | 3.0 |
Cell Cycle/*drug effects | 19 | 10.0 |
Cyclin D1/*metabolism | 4 | 6.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Down-Regulation/drug effects | 2 | 0.0 |
G2 Phase/drug effects | 3 | 6.0 |
S Phase/drug effects | 5 | 8.0 |
Carcinoma/*metabolism/pathology | 2 | 3.0 |
*Tumor Suppressor Proteins | 72 | 5.0 |
Up-Regulation/drug effects | 3 | 0.0 |
3T3 Cells | 11 | 0.0 |
Catalysis | 2 | 0.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Herpesvirus 8, Human/*genetics/physiology | 2 | 40.0 |
Histones/metabolism | 4 | 1.0 |
Macromolecular Substances | 5 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/metabolism | 3 | 2.0 |
Spodoptera/cytology | 2 | 4.0 |
Cell Transformation, Neoplastic | 4 | 0.0 |
Down-Regulation | 9 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Transcription Factors/*metabolism | 6 | 0.0 |
Cyclins/drug effects/metabolism | 3 | 16.0 |
Indoles/*pharmacology | 4 | 4.0 |
Retinoblastoma Protein/drug effects/metabolism | 4 | 23.0 |
Cell Cycle/*genetics | 5 | 6.0 |
*Oncogenes | 2 | 0.0 |
Cell Line | 36 | 0.0 |
DNA Mutational Analysis | 3 | 0.0 |
Gene Expression | 19 | 0.0 |
Hela Cells | 8 | 0.0 |
Microtubule-Associated Proteins/genetics/*metabolism | 3 | 7.0 |
Protein Binding/physiology | 2 | 0.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 2 | 0.0 |
G1 Phase/physiology | 10 | 13.0 |
Gene Expression Regulation, Neoplastic | 9 | 0.0 |
Protein-Serine-Threonine Kinases/*biosynthesis/genetics | 2 | 8.0 |
S Phase/physiology | 3 | 3.0 |
*Carrier Proteins | 6 | 1.0 |
Cell Transformation, Neoplastic/genetics | 3 | 1.0 |
DNA Damage | 2 | 0.0 |
DNA Replication | 5 | 1.0 |
Protein p16/physiology | 3 | 30.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors | 8 | 10.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 5 | 5.0 |
Neoplasms/genetics | 2 | 1.0 |
Protein p16/genetics/*physiology | 2 | 40.0 |
Protein p53/metabolism | 4 | 0.0 |
International Cooperation | 2 | 2.0 |
Cyclins/genetics | 3 | 2.0 |
*Enzyme Inhibitors | 15 | 37.0 |
*Gene Expression | 5 | 0.0 |
Hematopoietic Stem Cells/*metabolism | 2 | 1.0 |
Leukemia, Lymphocytic, Acute/genetics | 2 | 6.0 |
*Protein p16 | 10 | 27.0 |
*Saccharomyces cerevisiae Proteins | 4 | 0.0 |
CDC2 Protein Kinase/metabolism | 8 | 5.0 |
MAP Kinase Signaling System/*drug effects | 2 | 5.0 |
Mitosis/drug effects | 2 | 1.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 4 | 1.0 |
Mutagenesis | 6 | 0.0 |
Nuclear Proteins/metabolism | 4 | 0.0 |
Age Factors | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Disease Progression | 5 | 0.0 |
Disease-Free Survival | 3 | 0.0 |
Protein p16/*biosynthesis | 2 | 12.0 |
Breast Neoplasms | 3 | 1.0 |
DNA Replication/drug effects | 4 | 2.0 |
Enzyme Inhibitors/*pharmacology | 6 | 0.0 |
Spodoptera | 5 | 1.0 |
Growth Inhibitors/pharmacology | 2 | 1.0 |
Nitric Oxide/*metabolism | 2 | 1.0 |
Jurkat Cells | 8 | 0.0 |
Lymphocyte Activation/*immunology | 2 | 0.0 |
Cyclin E/metabolism | 11 | 9.0 |
DNA-Binding Proteins/metabolism | 5 | 0.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/*metabolism | 6 | 8.0 |
Purines/pharmacology | 2 | 3.0 |
Microtubule-Associated Proteins/*metabolism | 7 | 6.0 |
*Cell Differentiation | 3 | 1.0 |
Carrier Proteins/metabolism | 8 | 1.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/*metabolism | 7 | 14.0 |
Microtubule-Associated Proteins/metabolism | 12 | 8.0 |
Protein Kinase Inhibitors | 5 | 3.0 |
Protein p16 | 45 | 30.0 |
*Lymphocyte Activation | 3 | 0.0 |
Anticarcinogenic Agents/pharmacology | 2 | 7.0 |
Cell Survival/drug effects | 5 | 0.0 |
Cyclin E/physiology | 3 | 30.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/metabolism | 9 | 22.0 |
Cyclins/*physiology | 7 | 13.0 |
Protein-Serine-Threonine Kinases/*antagonists & inhibitors/metabolism | 5 | 15.0 |
Cell Division/*drug effects | 3 | 1.0 |
Cyclin-Dependent Kinases/genetics | 3 | 5.0 |
G0 Phase | 4 | 5.0 |
Cell Line, Transformed | 10 | 0.0 |
Lymphocyte Activation | 6 | 0.0 |
Signal Transduction/*physiology | 4 | 0.0 |
Cyclin D1/genetics/*metabolism | 2 | 10.0 |
Gene Expression Regulation, Neoplastic/drug effects | 4 | 0.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Apoptosis/drug effects | 8 | 1.0 |
Cell Transformation, Viral | 3 | 1.0 |
Cyclins/*genetics | 5 | 3.0 |
Retinoblastoma Protein/genetics/metabolism | 4 | 11.0 |
*Cell Aging | 3 | 5.0 |
Cell Size | 2 | 0.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/genetics/metabolism | 2 | 40.0 |
Enzyme Induction | 3 | 0.0 |
Protein p53/genetics/metabolism | 3 | 3.0 |
Recombinant Proteins/metabolism | 4 | 0.0 |
Telomerase/*antagonists & inhibitors/metabolism | 2 | 66.0 |
Blotting, Southern | 11 | 0.0 |
*Gene Deletion | 9 | 1.0 |
HL-60 Cells | 7 | 1.0 |
In Situ Hybridization, Fluorescence | 6 | 0.0 |
Microtubule-Associated Proteins/*genetics | 2 | 3.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Sequence Homology, Amino Acid | 16 | 0.0 |
*Cell Cycle | 10 | 4.0 |
Mitosis | 4 | 0.0 |
p14ARF Protein | 7 | 8.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
Melanoma/*genetics | 7 | 4.0 |
*Mutation | 6 | 0.0 |
Pedigree | 3 | 0.0 |
Polymorphism, Single-Stranded Conformational | 10 | 0.0 |
Sweden | 2 | 0.0 |
Chromatography, Gel | 3 | 0.0 |
Protein-Serine-Threonine Kinases/biosynthesis/metabolism | 2 | 40.0 |
Carrier Proteins/*genetics/metabolism | 6 | 2.0 |
Gene Deletion | 12 | 0.0 |
Protein-Serine-Threonine Kinases/*analysis/genetics | 2 | 40.0 |
Retrospective Studies | 2 | 0.0 |
Transplantation, Heterologous | 2 | 0.0 |
Arsenicals/*pharmacology | 4 | 15.0 |
Inhibitory Concentration 50 | 3 | 1.0 |
Oxides/*pharmacology | 4 | 17.0 |
*Germ-Line Mutation | 2 | 0.0 |
DNA, Complementary/genetics | 6 | 0.0 |
*Genes, Tumor Suppressor | 8 | 0.0 |
Point Mutation | 4 | 0.0 |
Carrier Proteins/*metabolism | 4 | 0.0 |
Enzyme Inhibitors/metabolism | 9 | 4.0 |
Lung Neoplasms/*metabolism | 2 | 2.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
Gene Transfer Techniques | 4 | 0.0 |
Herpesvirus 4, Human | 2 | 1.0 |
Receptors, Retinoic Acid/*metabolism | 2 | 3.0 |
Signal Transduction/drug effects | 4 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Carrier Proteins/genetics/*metabolism | 7 | 1.0 |
Cell Differentiation/drug effects | 5 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Cyclin-Dependent Kinases/physiology | 3 | 11.0 |
Melanoma/*pathology | 2 | 3.0 |
Cyclin-Dependent Kinases/genetics/*metabolism | 4 | 6.0 |
Cyclins/genetics/*metabolism | 10 | 12.0 |
DNA Methylation | 5 | 0.0 |
Homozygote | 8 | 0.0 |
Protein p16/genetics/*metabolism | 3 | 16.0 |
Retinoblastoma Protein/genetics/*metabolism | 2 | 4.0 |
Phosphoproteins/metabolism | 3 | 0.0 |
*Proteins | 4 | 0.0 |
S Phase/*physiology | 2 | 4.0 |
Androstadienes/pharmacology | 2 | 0.0 |
Cell Cycle/drug effects/*physiology | 2 | 4.0 |
Chromones/pharmacology | 2 | 0.0 |
G2 Phase | 4 | 2.0 |
Morpholines/pharmacology | 2 | 0.0 |
Lovastatin/*pharmacology | 2 | 9.0 |
Cyclin A/metabolism | 4 | 5.0 |
Protein Kinases/metabolism | 3 | 0.0 |
Cyclin-Dependent Kinases/*drug effects/metabolism | 3 | 60.0 |
Alkaloids/*pharmacology | 2 | 3.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
Sequence Deletion | 5 | 0.0 |
Translocation, Genetic | 3 | 0.0 |
DNA, Neoplasm/analysis | 3 | 0.0 |
Exons | 2 | 0.0 |
Proteins/*genetics | 2 | 0.0 |
Blood Physiology | 2 | 2.0 |
COS Cells | 7 | 0.0 |
Carrier Proteins/*physiology | 2 | 0.0 |
Cell Cycle/physiology | 8 | 2.0 |
Cercopithecus aethiops | 2 | 0.0 |
*Nuclear Proteins | 7 | 0.0 |
Saccharomyces cerevisiae | 3 | 1.0 |
*Transcription, Genetic | 2 | 0.0 |
Transcription Factors/metabolism | 5 | 0.0 |
Bone Neoplasms | 2 | 9.0 |
Osteosarcoma | 2 | 2.0 |
Cell Division/physiology | 7 | 0.0 |
DNA/biosynthesis | 3 | 0.0 |
In Vitro | 4 | 0.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Alleles | 3 | 0.0 |
Retroviridae/genetics | 4 | 1.0 |
G1 Phase/*genetics | 2 | 9.0 |
DNA Primers/genetics | 9 | 0.0 |
Oncogene Proteins/*genetics | 2 | 1.0 |
G1 Phase/immunology | 2 | 40.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
Mitogens/pharmacology | 2 | 0.0 |
Phytohemagglutinins/pharmacology | 3 | 0.0 |
Cell Nucleus/chemistry | 3 | 1.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Variation (Genetics) | 5 | 0.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
Exons/genetics | 2 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Chromosomes, Human, Pair 9 | 2 | 1.0 |
Phenotype | 2 | 0.0 |
Biological Transport | 3 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Interleukin-2/biosynthesis | 2 | 0.0 |
Apoptosis/*genetics | 3 | 1.0 |
Interleukin-6/*pharmacology | 2 | 0.0 |
Neurons/*cytology | 2 | 3.0 |
Cell Differentiation/genetics | 6 | 2.0 |
*Photochemotherapy | 2 | 4.0 |
Rabbits | 3 | 0.0 |
Enzyme Inhibitors | 6 | 7.0 |
Cyclin-Dependent Kinases/genetics/metabolism | 2 | 7.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
Gene Amplification | 3 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Herpesvirus 8, Human/genetics/*metabolism/pathogenicity | 2 | 100.0 |
Enzyme Inhibitors/*metabolism | 5 | 6.0 |
Escherichia coli/genetics | 2 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Protein p16/*chemistry/genetics | 2 | 100.0 |
Glutathione Transferase/metabolism | 4 | 0.0 |
Serine/metabolism | 2 | 0.0 |
Carrier Proteins/*genetics | 13 | 1.0 |
Genes, Tumor Suppressor/*genetics | 5 | 1.0 |
*Point Mutation | 2 | 0.0 |
Ankyrins/*chemistry | 2 | 50.0 |
Enzyme Inhibitors/*chemistry | 2 | 11.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Genes, p53/*genetics | 2 | 0.0 |
Transfection/genetics | 2 | 1.0 |
Cyclin D1/analysis | 2 | 5.0 |
Cyclin E/analysis | 2 | 13.0 |
Cyclins/*analysis | 3 | 7.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
*Alternative Splicing | 2 | 0.0 |
Feedback | 2 | 1.0 |
Protein p53/*metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 4 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Immunoglobulin M/immunology | 2 | 1.0 |
Proteins | 2 | 3.0 |
Tonsil/cytology | 2 | 2.0 |
Acetamides/*pharmacology | 2 | 16.0 |
Protein p16/metabolism | 5 | 8.0 |
Calcitriol/*pharmacology | 2 | 1.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
*G1 Phase | 5 | 10.0 |
Mutation/genetics | 2 | 0.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Cyclins/*biosynthesis | 4 | 7.0 |
Apoptosis/*drug effects/physiology | 2 | 1.0 |
Cell Cycle/*drug effects/physiology | 2 | 15.0 |
Signal Transduction/drug effects/physiology | 2 | 0.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Breast Neoplasms/metabolism/*pathology | 2 | 2.0 |
Cell Adhesion/drug effects | 2 | 0.0 |
Survival Analysis | 2 | 0.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
Silymarin/*pharmacology | 2 | 11.0 |
Genes, p16/*genetics | 3 | 6.0 |
Tumor Cells, Cultured/drug effects | 3 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Cell Nucleus/enzymology | 3 | 3.0 |
Nuclear Proteins/*metabolism | 2 | 0.0 |
Reference Values | 2 | 0.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
Cyclins/genetics/metabolism | 2 | 3.0 |
Chromosomes, Human, Pair 9/*genetics | 2 | 1.0 |
*Gene Expression Regulation | 6 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
Viral Proteins/genetics/*metabolism | 2 | 3.0 |
Cyclin-Dependent Kinases/genetics/metabolism/*physiology | 2 | 40.0 |
Mammals | 3 | 0.0 |
Drug Interactions | 2 | 0.0 |
*Protein Kinase Inhibitors | 7 | 11.0 |
Microtubule-Associated Proteins/*physiology | 2 | 8.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Carrier Proteins/*biosynthesis/genetics | 2 | 3.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Cyclin D1 | 19 | 14.0 |
Microinjections | 2 | 0.0 |
DNA/metabolism | 3 | 0.0 |
Dogs | 2 | 0.0 |
Microtubule-Associated Proteins/pharmacology | 2 | 50.0 |
Retinoblastoma Protein/genetics | 3 | 8.0 |
Breast/*cytology | 2 | 5.0 |
Epithelial Cells | 4 | 0.0 |
*Drosophila Proteins | 2 | 0.0 |
Oncogene Proteins/metabolism | 3 | 3.0 |
Cyclin-Dependent Kinases/*biosynthesis | 2 | 6.0 |
Protein-Serine-Threonine Kinases/*biosynthesis | 2 | 6.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
T-Lymphocytes | 2 | 0.0 |
Cyclins/analysis | 2 | 4.0 |
Epithelium/enzymology | 2 | 5.0 |
Cell Transformation, Neoplastic/*genetics | 2 | 1.0 |
Esophageal Neoplasms/*genetics/pathology | 2 | 6.0 |
Macrophages/cytology/metabolism | 2 | 8.0 |
Karyotyping | 2 | 0.0 |
Oncogene Proteins/genetics/*metabolism | 2 | 4.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Carrier Proteins/genetics/*physiology | 2 | 2.0 |
Cyclins/genetics/*physiology | 3 | 30.0 |
Cyclin-Dependent Kinases/*genetics | 3 | 4.0 |
Retinoblastoma Protein/*genetics | 2 | 4.0 |
Cyclin-Dependent Kinases/isolation & purification/metabolism | 2 | 50.0 |
Consensus Sequence | 3 | 0.0 |
*Chromosomes, Human, Pair 9 | 3 | 1.0 |
Cell Cycle Proteins/analysis | 2 | 7.0 |
Antimetabolites, Antineoplastic/pharmacology | 2 | 2.0 |
Protein Synthesis Inhibitors/*pharmacology | 2 | 6.0 |
Escherichia coli | 3 | 0.0 |
Recombinant Proteins | 3 | 0.0 |
Molecular Weight | 2 | 0.0 |
Acute Disease | 3 | 0.0 |
DNA, Neoplasm/metabolism | 2 | 1.0 |
Neoplasms/*genetics | 2 | 0.0 |
Protein Kinases/*metabolism | 3 | 0.0 |
Carrier Proteins/genetics/*isolation & purification/metabolism | 2 | 40.0 |
Chromosome Aberrations | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/*metabolism | 2 | 15.0 |
Oncogene Proteins/*metabolism | 2 | 2.0 |
Ligands | 2 | 0.0 |
Protein Kinases/*analysis | 2 | 28.0 |
Cell Proliferation/drug effects | 2 | 2.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 2 | 0.0 |
*Protein-Serine-Threonine Kinases | 2 | 0.0 |
Poly(ADP-ribose) Polymerases/metabolism | 2 | 1.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
Cyclin-Dependent Kinases/drug effects/metabolism | 2 | 13.0 |
*Muscle Proteins | 4 | 1.0 |
Amino Acid Substitution | 2 | 0.0 |
Monensin/*pharmacology | 2 | 50.0 |
Apoptosis/genetics | 2 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
